Search research articles
Contact Us
Filters
Showing results (401-410 of 551) with videos related to
Page
of 56
Sort By:
Plos One
|
March 15, 2011
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial
Mary S Campbell, James I Mullins, James P Hughes, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Research Square
|
September 8, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Human Vaccines & Immunotherapeutics
|
July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
Yunda Huang, Lily Zhang, Amanda Eaton, et al.
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
JCI Insight
|
June 22, 2021
Distinct populations of antigen-specific tissue-resident CD8+ T cells in human cervix mucosa
Tao Peng, Khamsone Phasouk, Emily Bossard, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Edward Weinstein, Roger Paredes, Annie Gardner, et al.
Scientific Reports
|
December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Vaccine
|
November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
Paul Spearman, Spyros Kalams, Marnie Elizaga, et al.
PLOS Global Public Health
|
September 11, 2025
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study
Nonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, et al.
Page
of 56
Search research articles
Search
Showing results (401-410 of 551) with videos related to
Sort By:
Page
of 56
Plos One
|
March 15, 2011
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial
Mary S Campbell, James I Mullins, James P Hughes, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Research Square
|
September 8, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Human Vaccines & Immunotherapeutics
|
July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
Yunda Huang, Lily Zhang, Amanda Eaton, et al.
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
JCI Insight
|
June 22, 2021
Distinct populations of antigen-specific tissue-resident CD8+ T cells in human cervix mucosa
Tao Peng, Khamsone Phasouk, Emily Bossard, et al.
The Lancet. Infectious Diseases
|
July 17, 2025
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial
Edward Weinstein, Roger Paredes, Annie Gardner, et al.
Scientific Reports
|
December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
Yunda Huang, Oleg Borisov, Jia Jin Kee, et al.
Vaccine
|
November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
Paul Spearman, Spyros Kalams, Marnie Elizaga, et al.
PLOS Global Public Health
|
September 11, 2025
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study
Nonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, et al.
Page
of 56